


REMARKS

The foregoing further aligns language with the examiner's suggestions.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: ALBRE-20

Date: May 29, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend the claims as follows:

2. (Amended) [Monoclonal antibodies] A monoclonal antibody according to claim 1 which [are] is available through:

- a. production of hybridoma cells enabled to produce monoclonal human-CD28 specific animal antibodies by means of an immunization with non- T tumor cell lines on which human CD28 is expressed,
- b. [if applicable] optionally, humanization of the monoclonal animal antibodies available from the hybridoma cells pursuant to A. above through a biochemical or gene-technological exchange of constant components of the animal antibodies against analogous constant components of a human antibody or replacement of genes of the hybridoma cells corresponding to the components; and
- c. secreting of the monoclonal antibodies in a hybridoma cell culture and isolation of the monoclonal antibodies from it or production of the monoclonal antibodies by injection of the hybridoma cells into animals, [for example mice,] and isolation of the monoclonal antibodies from the body fluid of the animals.

3. (Amended) [Monoclonal antibodies] A monoclonal antibody according to [claims 1 or 2] claim 1, with the hybridoma cells enabled to produce monoclonal human-CD28 specific animal antibodies being available through

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the SalI-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,

- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,
- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 by means of polyethylene glycol,
- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind on human CD28 expressing mouse A20J and/or L929 cells, and
- h) cultivation/sub-cloning of the selected hybridoma cells obtained in g) above and isolating the monoclonal antibodies.

4. (Amended) [Hybridoma cells] A hybridoma cell for the production of a monoclonal [antibodies] antibody according to [one of the claims 1 to 3] claim 1, which [are] is available through the following [procedural steps]:

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the Sall-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,
- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,
- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 by means of polyethylene glycol, and

- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind on human CD28 expressing mouse A20J and/or L929 cells.

13. (Amended) [Monoclonal antibodies] A monoclonal antibody according to claim 2, [with the hybridoma cells] enabled to produce monoclonal human-CD28 specific animal antibodies being available through

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the Sall-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,
- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,
- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 by means of polyethylene glycol,
- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind [on] human CD28 expressing mouse A20J and/or L929 cells, and
- h) cultivation/sub-cloning of the selected hybridoma cells obtained in g) above and isolating of the antibodies therefrom.

14. (Amended) [Hybridoma cells] A hybridoma cell for the production of a monoclonal [antibodies] antibody according to claim 2 which [are] is available through the following [procedural steps]:

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the SalI-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing [of] the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,
- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,
- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 [by means of] using polyethylene glycol, and
- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind [on] human CD28 expressing mouse A20J and/or L929 cells.

15. (Amended) [Hybridoma cells] A hybridoma cell for the production of a monoclonal [antibodies] antibody according to claim 3 which [are] is available through the following [procedural steps]:

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the SalI-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,
- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,

- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 [by means of] using polyethylene glycol, and
- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind [on] human CD28 expressing mouse A20J and/or L929 cells.

24. (Amended) [Hybridoma cells] A hybridoma cell for the production of a monoclonal [antibodies] antibody according to claim 13 which [are] is available through the following [procedural steps]:

- a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pH β APr-1-neo vector following excision of the SalI-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid,
- b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells [by means of] using polyethylene glycol,
- c) cultivation of the transfected cells received in b) above,
- d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28,
- e) immunization of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28,
- f) removal of spleen cells of the mice immunized in this way and fusing the spleen cells with cells of the cell line X63-Ag 8.653 [by means of] using polyethylene glycol, and
- g) selection of the hybridoma cells received in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind [on] human CD28 expressing mouse A20J and/or L929 cells.